CytomX Therapeutics Inc. reported a loss of $0.22 per share for its fourth quarter of 2025, a miss against the consensus estimate of a $0.08 loss. Revenue for the quarter was $0.66 million, falling far short of the $7.35 million consensus estimate. The loss was larger than the $0.09 per share loss reported in Q3 2025 and the $0.22 per share profit recorded in Q4 2024, while revenue dropped from $38.09 million in Q4 2024 to $0.66 million in Q4 2025.
The revenue shortfall was largely driven by the completion of collaboration obligations with Bristol Myers Squibb and reduced performance from ongoing partnerships with Moderna, Astellas, and Regeneron. These developments ended the company’s ability to generate the recurring revenue streams that had supported higher earnings in prior periods.
For the first quarter of 2026, CytomX guided to a loss of $0.10 per share on $5.62 million in revenue, and for the full fiscal year 2026 it expects a loss of $0.43 per share on $17.43 million in revenue. The guidance reflects continued losses but a lower revenue outlook, signaling management’s cautious view of near‑term revenue growth while maintaining focus on research and development.
CEO Sean McCarthy said, "Today's encouraging Varseta‑M Phase 1 update underscores the program's intentional design and broad potential in CRC as well as other EpCAM‑expressing indications. CytomX's top priority in 2026 is to align with the FDA on a registrational path for Varseta‑M in late‑line CRC." CFO Chris Ogden added, "Our top company priority is now to move Varseta forward aggressively into its first registrational study." The comments highlight the company’s strategic emphasis on advancing its lead candidate and validating its proprietary PROBODY platform.
Investors responded strongly to the Phase 1 clinical data for Varseta‑M, which validated the PROBODY platform and de‑risked the asset’s development path. The clinical breakthrough was the primary driver of the market reaction, outweighing the earnings miss and revenue shortfall.
Despite the quarterly miss, CytomX ended 2025 with $137.1 million in cash, cash equivalents, and investments, providing a runway to the second quarter of 2027. The company’s focus on R&D and the promising clinical data for Varseta‑M suggest that long‑term prospects remain tied to the success of its pipeline rather than short‑term financial performance.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.